Abstract: Some embodiments perform fully unsupervised string error detection and repair, for strings containing both syntactic errors and semantic errors. In some embodiments, string error mitigation includes learning a regular-expression-based pattern that characterizes at least a predefined fraction of a set of string data values, identifying and masking a semantic substring, deriving edits to repair a string which contains the semantic substring, and replacing a mask value with a replacement substring that conforms to the pattern. Some embodiments utilize a language model. Some embodiments include or utilize a pattern learner, one or more learned significant patterns, and a repair engine. Some embodiments exploit program execution information to generate patterns when significant patterns are not initially found.

Abstract: Some embodiments automatically generate data processing rules based on positive examples of processed data, e.g., formatting rules based on formatted data, filtering rules based on filtered data, or validating rules based on valid data. Some embodiments also use negative examples, e.g., unformatted data. A machine learning rule generation architecture includes a predicate generator, a cell cluster creator, a rule enumerator, and in some versions a rule ranker. Formatting rules written by a user are replaced by simpler autogenerated rules. Spreadsheet formatting rule functionality is enhanced, and surfaced in a user interface.

Abstract: A biocompatible intravaginal device adapted for the delivery of therapeutic active ingredients (agents) is provided. The device is constructed to be insertable and remain in the vagina for up to a month (28 to 31 days) or more. The device is loaded with the active agents prior to insertion and constructed to continuously release a therapeutically effective amount of the agents during the duration of up to a one month insertion. Preferred agents include contraceptive and anti-infection agents. It is preferred that the agents are non-hormonal.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

Abstract: The present invention relates to a chimeric nucleic acid molecule encoding a fusion protein having a human lutropin hormone-receptor domain and a human chorionic gonadotropin-? subunit domain, the isolated human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein, and antibodies which recognize part or all the domains of the fusion protein. Also provided are compositions having the human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein and a pharmaceutical carrier and compositions including antibodies to the fusion protein and a pharmaceutical carrier.

Abstract: An intravaginal contraceptive device has a biocompatible support structure constructed and configured to be inserted into a mammal's vagina without substantially blocking the cervix, coated by a multilayer coating having one or more biodegradable polymers. The multilayer coating can be constructed and formed of materials such that the multilayer coating dissolves over a period of at least three days, wherein each layer of the multilayer coating includes a spermicidal and/or spermiostatic composition and is constructed and formed to dissolve at varying times. Additionally, the multilayer coating is preferably constructed and formed of materials effective to provide a sustained release of a spermicidally or spermiostatically effective amount of the composition for at least three days.

Abstract: The present invention relates to a chimeric nucleic acid molecule encoding a fusion protein having a human lutropin hormone-receptor domain and a human chorionic gonadotropin-? subunit domain, the isolated human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein, and antibodies which recognize part or all the domains of the fusion protein. Also provided are compositions having the human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein and a pharmaceutical carrier and compositions including antibodies to the fusion protein and a pharmaceutical carrier.